Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 75 for:    stem cell multiple sclerosis
Previous Study | Return to List | Next Study

Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01377870
Recruitment Status : Completed
First Posted : June 21, 2011
Last Update Posted : March 7, 2018
Sponsor:
Information provided by (Responsible Party):
Royan Institute

Tracking Information
First Submitted Date  ICMJE June 19, 2011
First Posted Date  ICMJE June 21, 2011
Last Update Posted Date March 7, 2018
Study Start Date  ICMJE December 2011
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 20, 2011)
  • MRI metrics changes [ Time Frame: 6 months ]
    evaluate the effect of mesenchymal stem cell transplantation on number of GD positive lesions.
  • Brain atrophy [ Time Frame: 12 months ]
    evaluate the effect of mesenchymal stem cell transplantation to improve brain atrophy
  • number of sever relapses [ Time Frame: 6 months ]
    evaluation the effect of mesenchymal stem cell transplantation on number of sever relapses
  • EDSS [ Time Frame: 6 months ]
    Evaluation the effect of mesenchymal stem cells on progression of disease based on EDSS
  • MSFC [ Time Frame: 6 months ]
    Evaluation the effect of mesenchymal stem cells transplantation on MSFC
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01377870 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 20, 2011)
  • quality of life [ Time Frame: 6 months ]
    Evaluation the effect of mesenchymal stem cell transplantation on patients quality of life
  • RAO Test [ Time Frame: 6 months ]
    Evaluation the effect of mesenchymal stem cell transplantation on RAO Test.
  • intravenous cell transplantation [ Time Frame: 6 months ]
    evaluation the side effect of intravenous transplantation of mesenchymal stem cell
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis
Official Title  ICMJE Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis
Brief Summary

Multiple sclerosis is a multifocal inflammatory disease of the central nervous system which affects young individuals and causes paralysis of the limbs, sensation, visual and sphincter problems. The disease is caused by an autoimmune mechanism, ie the immune system produces antibodies and cells which attack the self myelin antigens, causing therefore demyelination. The disease is clinically evident with relapses of neurological disability due to the dysfunction of the areas (plaques of multiple sclerosis) in which damage of myelin occurs. Disability can accumulate with time and the disease enters a progressive phase due to damage of the axons and irreversible neurodegeneration. Although, effective immunotherapies exist which downregulate the autoimmune anti-myelin reactivity and reduce the rate of relapses of MS (like Copaxone and interferons), there is no effective means today to stop the progression of disability and induce rebuilding of the destroyed myelin.Adult bone marrow derived stromal cells (MSC) were shown to induce similar (to the neuronal stem cells) immunomodulatory and neuroregenerative effects and were shown in our laboratory to induce neuroprotection in the animal model of chronic experimental autoimmune encephalomyelitis (EAE). These bone marrow derived MSCs offer practical advantages for clinical therapeutic applications, since they can be obtained from the adult bone marrow and therefore the patient can be the donor for himself, without any danger for rejection of the cells. In addition, MSCs carry a safer profile and are less prone to malignant transformation.

Our center will perform a clinical trial with intra venous transplantation of bone marrow derived mesenchymal stem cell.our purpose is to evaluate the safety and feasibility of cell transplantation after 1year following up.

Detailed Description In the clinical trial 30 patients with multiple sclerosis who are drug resistance will take apart.Based on inclusion and exclusion criteria patients are chosen.Bone marrow aspiration will be done for all of them under local anesthesia.Patients are randomly divided in 2 groups:case and control. Then mesenchymal stem cells which are separated and prepared will be transplanted by intravenous injection to the patients in case group and the cells which obtain from patients in control group are frozen and inject after 6 months. Patients will be followed by Evaluation of EDSS MSFC RAO Test brain and cervical MRI and quality of life questionnaire after 1th 3th 6th and 12th months after transplantation.all these tests will be done before transplantation as basic evaluation.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Multiple Sclerosis
Intervention  ICMJE
  • Biological: intravenous injection of mesenchymal stem cells
    15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
    Other Name: stem cell transplantation
  • Biological: injection of cell free media
    Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
    Other Name: control group
Study Arms  ICMJE
  • Placebo Comparator: cell free media
    15 patients with relapsing remitting multiple sclerosis who receive cell free media
    Intervention: Biological: injection of cell free media
  • Experimental: mesenchymal stem cell reciepiants
    Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
    Intervention: Biological: intravenous injection of mesenchymal stem cells
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 24, 2014)
22
Original Estimated Enrollment  ICMJE
 (submitted: June 20, 2011)
30
Actual Study Completion Date  ICMJE April 2014
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Both gender
  • Age: 18-55years
  • Duration of disease: 2-10 years
  • Relapsing remitting with drug resistance
  • EDSS: 3-6.5
  • Resistance to immunomodulatory and cytotoxic drugs:

    • At least 1-2 sever relapse during 1 year drug treatment
    • At least increase 1 point of EDSS during 1 year drug treatment
  • Secondary progressive or relapsing multiple sclerosis
  • Primary progressive MS with relapse or GAD positive enhancement
  • Secondary progressive MS with relapse
  • Secondary progressive MS without relapse:progression of disease with 1 point increase of EDSS during last 18 months

Exclusion Criteria:

  • Pregnancy positive test
  • Under treatment with cytotoxic drugs at the same time or during last 3 months
  • Under treatment with immunomodulatory drugs at the same time or during last month
  • Relapse of disease 30 days or less than 30 days before transplantation
  • Primary progressive MS with out relapse or GAD positive enhancement
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Iran, Islamic Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01377870
Other Study ID Numbers  ICMJE Royn-nerve-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Royan Institute
Study Sponsor  ICMJE Royan Institute
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Hamid Gourabi, PhD head of Royan Institute
Study Director: Nasser Aghdami, MD,PhD Head of cell therapy center of Royan Institute
Principal Investigator: Masoud Nabavi, MD scientist and clinician
Principal Investigator: Leila Arab, MD Department of regenerative medicine,Royan Institute
PRS Account Royan Institute
Verification Date August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP